Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00143247 · ClinicalTrials.gov registry record · Phase 2

Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus

A Phase 2 study, sponsored by Pfizer.

Terminated
Registry status
Phase 2
Development phase
173
Enrollment target

NCT00143247: Clinical Trial Phase 2 study, sponsored by Pfizer.

NCT00143247 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 173 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (30% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00143247, a Phase 2 study, was terminated before completion, sponsored by Pfizer.

TERMINATED
Registry status
Phase 2
Development phase
173 participants
Enrollment target

Study Summary

This is a long-term safety study for Phase 2 subjects who choose to remain on Exubera® (inhaled insulin).

Primary Outcome

Change from Baseline: mean of (value of observed forced expiratory volume in 1 second (FEV1) (liters) at treatment duration minus baseline value). Duration of treatment is based on the elapsed duration of treatment in the controlled and uncontrolled studies. Baseline was based on pre-inhaled insulin measurements.

Interventions

  • DRUG Exubera® (inhaled insulin)

Trial Details

FieldValue
Enrollment Target 173 participants
Start Date 2003-03
Est. Completion 2008-01
Phase Phase 2
Pfizer

1,845 total trials

Why NCT00143247 stopped before completion

NCT00143247 is an interventional study that assigns participants to a tested intervention. The registered 173 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (30% higher).

The record links to 0 conditions, and to 1 intervention - of which Exubera® (inhaled insulin) is the first listed.

NCT00143247 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00143247 about?

NCT00143247 is a clinical study titled "Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus". This is a long-term safety study for Phase 2 subjects who choose to remain on Exubera® (inhaled insulin).

What is the current status of trial NCT00143247?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 173 participants. The study started on 2003-03. Estimated completion is 2008-01.

What interventions are being tested in trial NCT00143247?

The interventions under investigation include: Exubera® (inhaled insulin) (DRUG).

Who is sponsoring clinical trial NCT00143247?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00143247's enrollment target sits among peer trials

173 397th of 2000 higher than 1,604 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05568719 · 173 participants · Phase 3

    Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

  • NCT07070115 · 173 participants · NA

    Evaluating Clinical Hiatal Hernia Outcomes Using OviTex®

  • NCT07150832 · 173 participants · NA

    Efficacy of the I-CARE Digital Health Intervention

  • NCT01000259 · 174 participants

    Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00143247, the US trial registry maintained by the National Library of Medicine. NCT00143247 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.